MXPA02008253A - Metodos de diseno de farmacos basados en la estructura usando em/rmn. - Google Patents

Metodos de diseno de farmacos basados en la estructura usando em/rmn.

Info

Publication number
MXPA02008253A
MXPA02008253A MXPA02008253A MXPA02008253A MXPA02008253A MX PA02008253 A MXPA02008253 A MX PA02008253A MX PA02008253 A MXPA02008253 A MX PA02008253A MX PA02008253 A MXPA02008253 A MX PA02008253A MX PA02008253 A MXPA02008253 A MX PA02008253A
Authority
MX
Mexico
Prior art keywords
compound
complex
target
compounds
molecule
Prior art date
Application number
MXPA02008253A
Other languages
English (en)
Spanish (es)
Inventor
Robert Powers
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA02008253A publication Critical patent/MXPA02008253A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA02008253A 2000-02-25 2001-02-21 Metodos de diseno de farmacos basados en la estructura usando em/rmn. MXPA02008253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51380600A 2000-02-25 2000-02-25
PCT/US2001/005495 WO2001062688A2 (fr) 2000-02-25 2001-02-21 Procede de conception de medicaments fondes sur la structure utilisant la spectrometrie de masse et la resonance magnetique nucleaire

Publications (1)

Publication Number Publication Date
MXPA02008253A true MXPA02008253A (es) 2002-11-29

Family

ID=24044740

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008253A MXPA02008253A (es) 2000-02-25 2001-02-21 Metodos de diseno de farmacos basados en la estructura usando em/rmn.

Country Status (9)

Country Link
EP (1) EP1259469A2 (fr)
JP (1) JP2003524167A (fr)
CN (1) CN1411554A (fr)
AR (1) AR027955A1 (fr)
AU (1) AU2001238584A1 (fr)
BR (1) BR0108606A (fr)
CA (1) CA2401014A1 (fr)
MX (1) MXPA02008253A (fr)
WO (1) WO2001062688A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044185A2 (fr) * 2001-11-21 2003-05-30 Affinium Pharmaceuticals, Inc. Nouveaux polypeptides purifies iimpliques dans un metabolisme general

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
AU711092B2 (en) * 1995-11-14 1999-10-07 Abbvie Inc. Use of nuclear magnetic resonance to design ligands to target biomolecules
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
ES2213823T3 (es) * 1996-04-08 2004-09-01 Glaxo Group Limited Codificacion y analisis cualitativo de bibliotecas combinatorias basadas en masa.
CA2362052A1 (fr) * 1999-02-12 2000-08-17 Cetek Corporation Recherche systematique de ligands affinitaires dans des materiaux biologiques complexes par un procede haut debit a exclusion par taille

Also Published As

Publication number Publication date
EP1259469A2 (fr) 2002-11-27
JP2003524167A (ja) 2003-08-12
WO2001062688A3 (fr) 2002-03-14
WO2001062688A2 (fr) 2001-08-30
CA2401014A1 (fr) 2001-08-30
BR0108606A (pt) 2003-01-07
AR027955A1 (es) 2003-04-16
AU2001238584A1 (en) 2001-09-03
CN1411554A (zh) 2003-04-16

Similar Documents

Publication Publication Date Title
Hüttenhain et al. Perspectives of targeted mass spectrometry for protein biomarker verification
Wales et al. Hydrogen exchange mass spectrometry for the analysis of protein dynamics
Chahrour et al. Stable isotope labelling methods in mass spectrometry-based quantitative proteomics
Zhang et al. Human recombinant [C22A] FK506‐binding protein amide hydrogen exchange rates from mass spectrometry match and extend those from NMR
US7501286B2 (en) Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
EP1472539B1 (fr) Quantification absolue de proteines et de formes modifiees de proteine par spectrometrie de masse multistade
EP2286237B1 (fr) Analyse spectrométrique de masse
JP4672615B2 (ja) 迅速かつ定量的なプロテオーム解析および関連した方法
Schneider et al. Stable isotope methods for high-precision proteomics
US6829539B2 (en) Methods for quantification and de novo polypeptide sequencing by mass spectrometry
US20060008851A1 (en) Methods for rapid and quantitative proteome analysis
CN105143872A (zh) 通过质谱分析用复用内标物对蛋白质和蛋白质修饰的绝对定量
US20020115056A1 (en) Rapid and quantitative proteome analysis and related methods
WO2003078962A2 (fr) Detection et quantification de proteines modifiees
CA2349265A1 (fr) Base de donnees de profil d'expression de proteines
Jethva et al. Hydrogen deuterium exchange and other mass spectrometry-based approaches for epitope mapping
Pisitkun et al. Tandem mass spectrometry in physiology
MXPA02008253A (es) Metodos de diseno de farmacos basados en la estructura usando em/rmn.
US20010046684A1 (en) Methods of structure-based drug design using MS/MNR
Wang et al. Quantitative proteomics in development of disease protein biomarkers
BRPI0717854A2 (pt) Métodos para ligar covalentemente uma etiqueta de afinidade a uma proteína, para isolar peptídeos, para simultaneamente analisar a ocorrência de uma ou mais proteínas e, para identificar a presença de uma proteína em uma amostra de proteína, composto, conjunto de reagentes, uso de um composto ou do conjunto de reagentes marcadores, banco de dados de peptídeos, uso de banco de dados, e, dispositivo para análise e marcação por multiplexação de amostras de proteína
Thikekar et al. A review on-analytical tools in proteomics
Mandell et al. Application of amide proton exchange mass spectrometry for the study of protein‐protein interactions
Courouble et al. Advances in Mass Spectrometry‐Based Structural Proteomics: Development of HDX‐MS and XL‐MS Techniques from Recombinant Protein to Cellular Systems
Costongs et al. Evaluation of the Abbott Automated Random, Immediate and Continuous Access Immunoassay Analyser, the AxSYM [TM]